Further assessment should be carried out on larger cohorts, including a larger number of samples from KIT negative GIST and other mesenchymal gut tumors, to precisely determinate the place of PDE3A-ir in clinical pathology. This evidence concerns the gene PDE3A and gastrointestinal stromal tumor.